Company
Headquarters: Changsha, China
Employees: 1,273
CN¥8.09 Billion
CNY as of July 1, 2025
US$1.13 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Hunan Jiudian Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers antiallergic, anti-infective, and anti-inflammatory drugs; analgosies and gynecological medication products; digestive system products; chemical and Chinese patent medicines; medical instruments; APIs; and other products. It also provides outsourcing services for tablets, capsules, granules, oral solutions, syrups, etc. Hunan Jiudian Pharmaceutical Co., Ltd. is based in Changsha, China.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥3.04 B |
| EBITDA | CN¥593.1 M |
| Gross Profit TTM | CN¥2.22 B |
| Profit Margin | 16.88% |
| Operating Margin | 21.42% |
| Quarterly Revenue Growth | 17.80% |
Hunan Jiudian Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300705 wb_incandescent